A serum protein signature at the time of Uveal Melanoma diagnosis predicts long-term patient survival.

A prognostic test based on a single peripheral venous blood sample at the time of uveal melanoma diagnosis stratifies patients into low, intermediate, and high metastatic risk categories. Prospective validation will facilitate its clinical utility.